A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219

Trial Profile

A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs Buprenorphine/naloxone (Primary)
  • Indications Opioid abuse
  • Focus Adverse reactions
  • Sponsors Orexo
  • Most Recent Events

    • 22 Apr 2015 Results published in an Orexo media release.
    • 22 Apr 2015 Status changed from active, no longer recruiting to completed, based on an Orexo media release.
    • 27 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top